Chemotherapy engages multiple pathways leading to IL-1β production by myeloid leukocytes

OncoImmunology

Volumn 3, Issue 1, 2014, Pages

  Antonopoulos, Christina ^a   Dubyak, George R ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Caspase 1; Caspase 8; Chemotherapy; IL 1 ; Inflammasome; Ripoptosome

Indexed keywords

ANTINEOPLASTIC AGENT; BACULOVIRAL IAP REPEAT CONTAINING 2; CASPASE 8; CELL PROTEIN; CISPLATIN; CRYOPYRIN; DOXORUBICIN; ENDOTOXIN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLUOROURACIL; GEMCITABINE; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MITOXANTRONE; OXALIPLATIN; PROTEIN KINASE; RECEPTOR INTERACTING PROTEIN KINASE 1; RIPOPTOSOME; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; STAUROSPORINE; TOLL LIKE RECEPTOR 4; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; ANTITUMOR IMMUNE RESPONSE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL; CELL EXPANSION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DOWN REGULATION; DRUG EFFICACY; DRUG EXPOSURE; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LEUKOCYTE; MACROPHAGE; MYELOID DERIVED SUPPRESSOR CELL; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T LYMPHOCYTE; TRANSCRIPTION INITIATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR NECROSIS;

EID: 84899128564     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27499     Document Type: Article

References (10)

1. Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 2012; 13:343-51; PMID:22430787; http://dx.doi.org/10.1038/ni.2224.
2. Janowski AM, Kolb R, Zhang W, Sutterwala FS. Beneficial and Detrimental Roles of NLRs in Carcinogenesis. Front Immunol 2013; 4:370; PMID:24273542; http://dx.doi.org/10.3389/fimmu.2013.00370.
3. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8; PMID:19767732; http://dx.doi. org/10.1038/nm.2028.
4. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013; 13:397-411; PMID:23702978; http://dx.doi. org/10.1038/nri3452.
5. Sauter KA, Wood LJ, Wong J, Iordanov M, Magun BE. Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome. Cancer Biol Ther 2011; 11:1008-16; PMID:21464611; http://dx.doi. org/10.4161/cbt.11.12.15540.
6. Shimada K, Crother TR, Karlin J, Dagvadorj J, Chiba N, Chen S, Ramanujan VK, Wolf AJ, Vergnes L, Ojcius DM, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 2012; 36:401-14; PMID:22342844; http://dx.doi.org/10.1016/j.immuni.2012.01.009.
7. Bruchard M, Mignot G, Derangère V, Chalmin F, Chevriaux A, Végran F, Boireau W, Simon B, Ryffel B, Connat JL, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013; 19:57-64; PMID:23202296; http://dx.doi.org/10.1038/nm.2999.
8. Antonopoulos C, El Sanadi C, Kaiser WJ, Mocarski ES, Dubyak GR. Proapoptotic chemotherapeutic drugs induce noncanonical processing and release of IL-1β via caspase-8 in dendritic cells. J Immunol 2013; 191:4789-803; PMID:24078693; http://dx.doi.org/10.4049/jimmunol.1300645.
9. Mocarski ES, Upton JW, Kaiser WJ. Viral infection and the evolution of caspase 8-regulated apoptotic and necrotic death pathways. Nat Rev Immunol 2012; 12:79-88; PMID:22193709.
10. Vince JE, Wong WW, Gentle I, Lawlor KE, Allam R, O'Reilly L, Mason K, Gross O, Ma S, Guarda G, et al. Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation. Immunity 2012; 36:215-27; PMID:22365665; http://dx.doi. org/10.1016/j.immuni.2012.01.012.